Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction

Circulation

Volumn 94, Issue 9, 1996, Pages 2216-2220

  Weir, E Kenneth ^a,b   Reeve, Helen L ^a   Huang, James M C ^a   Michelakis, Evangelos ^a   Nelson, Daniel P ^a   Hampl, Vaclav ^a   Archer, Stephen L ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

hypertension, pulmonary; muscle, smooth; obesity; vasoconstriction

Indexed keywords

AMINOREX; DEXFENFLURAMINE; FENFLURAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY TONE; ARTICLE; DEPOLARIZATION; DRUG EFFECT; MALE; NONHUMAN; OBESITY; POTASSIUM CURRENT; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; RAT; VASCULAR SMOOTH MUSCLE;

EID: 0029825291     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.9.2216     Document Type: Article

References (39)

1. Gurtner H. Atiologie and haufigkeit der primar vaskularen formen des chronischen Cor pulmonale. Deutsche Med Wochen. 1969;94:850-852.
2. Mlczoch J. Drug and dietary induced pulmonary hypertension. In: Weir EK, Reeves JT. eds. Pulmonary Hypertension. New York, NY: Futura; 1984:341-359.
3. Douglas J, Munro J, Kitchin A, Muir A, Proudfoot A. Pulmonary hypertension and fenfluramine. Br Med J. 1981;283:881-883.
4. McMurray J, Bloomfield P, Miller H. Irreversible pulmonary hypertension after treatment with fenfluramine. Br Med J. 1986;292:239-240.
5. Pouwels H, Smeets J, Cheriex E, Wouters E. Pulmonary hypertension and fenfluramine. Eur Respir J. 1990;3:606-607.
6. Fotiadis I, Apostolou T, Koukoulas A, Michelacakis N, Kremastinos D. Fenfluramine-induced irreversible pulmonary hypertension. Post-grad Med J. 1991;67:776-777.
7. Atanasson P, Weiss B, Schmid E, Tornic M. Pulmonary hypertension and dexfenfluramine. Lancet. 1992;339:436.
8. Roche N, Labrune S, Braun J, Huchon G. Primary hypertension and dexfenfluramine. Lancet. 1992;339:436-437.
9. Brenot F, Herve P, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J. 1993;70:537-541.
10. Thomas S, Butt A, Corris P, Egan J, Higenbottam T, Madden B, Waller P. Appetite suppressants and primary pulmonary hypertension in the United Kingdom. Br Heart J. 1995;74:660-663.
11. Cacoub P, Dorent R, Natlaf P, Houppe J, Piette J, Godeau P, Gandjbakhch I. Pulmonary hypertension and dexfenfluramine. Eur J Clin Pharmacol. 1995;48:81-83.
12. Voelker R. Obesity drug renews toxicity debate. JAMA. 1994;272:1087-1088.
13. Weir E, Archer S. The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels. FASEB J. 1995;9:183-189.
14. Voelkel N, Weir E. Etiologic mechanisms in primary pulmonary hypertension. In; Weir E, Reeves J, eds. Pulmonary Vascular Physiology and Pathophysiology. New York, NY: Marcel Dekker; 1989:513-539.
15. Post J, Hume J, Archer S, Weir E. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol. 1992;262:C882-C890.
16. Hamill O, Marty A, Nehr B, Sakmann B, Sigworth F. Improved patch clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981;391:85-100.
17. Rae J, Cooper K, Gates P, Watsky M. Low access resistance perforated patch recordings using amphotericin B. J Neurosci Methods. 1991;37:15-26.
18. Archer S, Huang J, Hampl V, Nelson D, Shultz P, Weir E. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci U S A. 1994;9:7583-7587.
19. Gomez-Sanchez M, Calzada C, Gomez-Pajuelo C, Martinez-Tello F, Juan M, Jamers T. Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome. J Am Coll Cardiol. 1991;18:1539-1545.
20. Guy-Grand B, Crepaldi G, Lefebvre P, Apfelbaum M, Gries A, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;2:1142-1144.
21. 2+-ATPase of the mammalian sarcoplasmic reticulum. J Biol Chem. 1993;268:4021-4024.
22. Dexfenfluramine. Lancet. 1991;337:1315-1316. Editorial.
23. Barer G, Emery C, Stewart A, Bee D, Howard P. Endothelial control of the pulmonary circulation in normal and chronically hypoxic rats. J Physiol. 1992;463:1-16.
24. Oka M, Hasunuma K, Webb S, Stelzner T, Rodman D, McMurtry I. EDRF suppresses an unidentified vasoconstrictor mechanism in hypertensive rat lungs. Am J Physiol. 1993;264:L587-L597.
25. Isaacson T, Hampl V, Weir E, Nelson D, Archer S. Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rats. J Appl Physiol. 1994;76:933-940.
26. Xue C, Rengasamy A, LeCras T, Koberna P, Dailey G, Johns R. Distribution of NOS in normoxic vs hypoxic rat lung: upregulation of NOS by chronic hypoxia. Am J Physiol. 1994;267:L667-L678.
27. Smith P, Heath D, Kay J, Wright J, McKendrick C. Pulmonary arterial pressure and structure in the Patas monkey after prolonged administration of aminorex furmarate. Cardiovasc Res. 1973;7:30-38.
28. Byrne-Quinn E, Grover R. Aminorex (Menocil) and amphetamine: acute and chronic effects on pulmonary and systemic haemodynamics in the calf. Thorax. 1972;27:127-131.
29. Engelhardt A, Kroneberg G, Stoepel K, Stotzer H. The effects of acute and chronic administration of sympathomimetic substances on the systemic and pulmonary circulation. Proc Eur Soc Drug Toxicol. 1970;11:110-117.
30. Kay J, Smith P, Heath D. Aminorex and the pulmonary circulation. Thorax. 1971;26:262-270.
31. Will J, Bisgard G. Haemodynamic effects of oral aminorex and amphetamine in unanaesthetized beagle dogs. Thorax. 1972;27:120-126.
32. Stepanek J, Zak F. Zweijahrige perorale applikation von aminorex am hund 2. Teil. Z Kardiol. 1975;64:768-781.
33. Loza J, Marzec N, Simasko S, Dziak R. Role of epidermal growth factor-induced membrane depolarization and resulting calcium influx in osteoblastic cell proliferation. Cell Calcium. 1995;17:301-306.
34. Loza J, Carpio L, Lawless G, Marzec N, Dziak R. Role of extracellular calcium influx in EGF-induced osteoblastic cell proliferation. Bone. 1995;16:341S-347S.
35. Mlczoch J, Weir E, Reeves J, Grover R. Long term effects of the anorectic agent fenfluramine alone and in combination with aminorex on pulmonary and systemic circulation in the pig. Basic Res Cardiol. 1979;74:313-320.
36. Naeije R, Wauthy P, Maggiorini M, Leeman M, Delcroix M. Effects of dexfenfluramine on hypoxic pulmonary vasoconstriction and embolic pulmonary hypertension in dogs. Am J Respir Crit Care Med. 1995;151:692-697.
37. McTavish D, Heel R. Dexfenfluramine: a review of its pharmacological properties and therapeutic potential in obesity. Drugs. 1992;43:713-733.
38. Premkumar L, Ahern G. Blockade of a resting potassium channel and modulation of synaptic transmission by ecstasy in the hippocampus. J Pharmacol Exp Ther. 1995;274:718-722.
39. Schaiberger P, Kennedy T, Miller F, Gal J, Petty T. Pulmonary hypertension associated with long term inhalation of 'crank' methamphetamine. Chest. 1993;104:614-616.